Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis

Takeda presented encouraging results from the Phase 2b trial (NCT05153148) at the November 2023 American College of Rheumatology (ACR) convergence in San Diego. The Phase 2b study evaluated TYK279 which…

Continue Reading Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis
Informing Treatment Decisions for Psoriatic Arthritis: A Discussion with Dr. Soumya Chakravarty
source: pixabay.com

Informing Treatment Decisions for Psoriatic Arthritis: A Discussion with Dr. Soumya Chakravarty

From November 10-14, 2022, various stakeholders within the rheumatology sphere connected at the American College of Rheumatology’s (ACR) Convergence 2022. During ACR Convergence, described as the world’s premier rheumatology experience,…

Continue Reading Informing Treatment Decisions for Psoriatic Arthritis: A Discussion with Dr. Soumya Chakravarty
Medical Professionals Discuss Guidelines for Psoriatic Arthritis
Aymanjed / Pixabay

Medical Professionals Discuss Guidelines for Psoriatic Arthritis

Recently, two medical professionals were interviewed where they discussed their recommendations for the guidelines pertaining to managing psoriatic arthritis. Psoriatic Arthritis Psoriatic arthritis is a type of inflammatory arthritis that…

Continue Reading Medical Professionals Discuss Guidelines for Psoriatic Arthritis

Axial PsA and axSpA Patient Populations are Found to Have Key Similarities and Differences

A recent study presented in early June showcased how, despite some similarities, psoriatic arthritis with axial involvement (axial PsA) patients and axial spondyloarthritis (axSpA) patients have meaningful differences. These findings…

Continue Reading Axial PsA and axSpA Patient Populations are Found to Have Key Similarities and Differences
Health Canada Approves Hyrimoz for Ankylosing Spondylitis
stevepb / Pixabay

Health Canada Approves Hyrimoz for Ankylosing Spondylitis

According to GlobeNewswire, Health Canada has approved of a biosimilar, Hyrimoz, to treat ankylosing spondylitis and eight other rare conditions. Sandoz Canada is excited about this approval, as it expands…

Continue Reading Health Canada Approves Hyrimoz for Ankylosing Spondylitis
Promising New Treatments Beyond the Standards for Spondyloarthropathies
source: pixabay.com

Promising New Treatments Beyond the Standards for Spondyloarthropathies

by Lauren Taylor from In The Cloud Copy Spondyloarthropathies is an umbrella term for a group of chronic diseases that affect the joints. These can affect children and adults and…

Continue Reading Promising New Treatments Beyond the Standards for Spondyloarthropathies
Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19
source: pixabay.com

Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19

Michael George and his team from the University of Pennsylvania have recently uncovered new insights regarding autoimmune patient’s comfortability with care during COVID-19. They've been working since the pandemic began…

Continue Reading Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19

Arthritis Treatment Shows Off-Target Benefits for Those Also Living with Diabetes

A recent study published in BMC Rheumatology has found that a combination therapy could have a benefit for individuals diagnosed with diabetes and ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis…

Continue Reading Arthritis Treatment Shows Off-Target Benefits for Those Also Living with Diabetes
Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
https://pixabay.com/en/baby-child-cute-doll-expression-17366/

Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…

Continue Reading Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Tennis Pro Caroline Wozniacki’s Advantage Hers Campaign Supports Women with Inflammatory Conditions

Caroline Wozniacki has led an interesting life. Born in Denmark, she was immediately thrust into athleticism. Her father was a former football player (that's soccer for you Americans) and her…

Continue Reading Tennis Pro Caroline Wozniacki’s Advantage Hers Campaign Supports Women with Inflammatory Conditions
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available
Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment
mohamed_hassan / Pixabay

Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

  In some cases, people have a medical condition that doesn't respond well to treatments. The journey to finding an effective treatment can be long and difficult. But for patients…

Continue Reading Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment